SpinChip announces publication of the APACE study in the Journal of the American College of Cardiology (JACC)

Oslo, Norway—14 August 2024—SpinChip announced today that the impressive results of its APACE (Advantageous Predictors of Acute Coronary Syndromes Evaluation) study, have been published in the esteemed peer-reviewed journal in cardiovascular medicine, the Journal of the American College of Cardiology (JACC).¹

In the article titled “Clinical and Analytical Performance of a Novel Point-of-Care High-Sensitivity Cardiac Troponin I Assay”, it is stated that the findings of the APACE study show the potential of the hs-cTnI-SPINCHIP POCT test to significantly improve the speed and accuracy of MI diagnosis in the Emergency Department (ED).²

The article also states that the comparable diagnostic performance of the hs-cTnI-SPINCHIP to central laboratory assays suggests that POC testing could become a valuable tool in the early triage and management of patients with suspected MI. An important strength of this assay is its high diagnostic accuracy.

Importantly, the article demonstrates that SpinChip’s technology can deliver diagnostic performance on par with well-validates central laboratory assays currently in world-wide clinical use. This supports the potential use of the technology in the ED to expedite MI diagnosis and treatment, potentially reducing ED overcrowding and health care costs.

Additionally, the article emphasises the high agreement between different sample types that supports the assay’s flexibility in various clinical settings, including prehospital care, general practice, and remote locations. This expands the potential applications of the hs-cTnI-SPINCHIP assay, making high-sensitivity troponin testing more accessible². 

Professor Christian Mueller, Principal investigator of the APACE study, commented:

“The novel Point-of-Care SpinChip high-sensitivity cardiac Troponin I test demonstrated comparable diagnostic performance with the best-validated central laboratory assays. The results are impressive and very good news for both patients and physicians.”

Morten Jurs, Chief Executive Officer of SpinChip Diagnostics ASA, added:

“SpinChip is proud to have developed a game-changing Point of Care IVD platform with great potential in reducing overcrowding and healthcare costs in the Emergency Departments. In addition, the SpinChip platform has the potential to become the broadest testing regime within Point of Care and expand into other settings such as prehospital care, general practices, and remote locations to make high-sensitivity testing more accessible. We are also pleased to see the positive results of the APACE study published in JACC and will continue to work with leading clinical trial organizations like Basel University Hospital and Akershus University Hospital to ensure that our unique technology reaches the market.”

END

 References:

1. J Am Coll Cardiol 2024;84:726 – 740
2. J Am Coll Cardiol 2024;84:741 – 743